Generic Name: dolutegravir

Pronunciation: TIV-eh-kay

Abbreviation: DTG

Other Market Name: N/A

Drug Class: Integrase Inhibitors

Company: ViiV Healthcare

Approval Status: Approved

Generic Version Available: No

Experimental Code: S/GSK1349572


Drug Indication

Tivicay is a recommended component of treatment regimens for previously untreated people living with HIV, as indicated by the U.S. Department of Health and Human Services (DHHS) Antiretroviral Guidelines for Adults and Adolescents. Visit https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0 for the full DHHS guidelines.


General Info

Tivicay is an HIV medication in a category called integrase inhibitors. Tivicay was approved by the U.S. Food and Drug Administration for use by people living with HIV in August 2013.

Tivicay must be used in combination with other HIV drugs. Tivicay is available as a stand-alone drug, for use in combination with other medications, or in the single-tablet regimens Triumeq (with abacavir and lamivudine), Juluca (with rilpivirine) and Dovato (with lamivudine).


Dosage

Adult Dose: One 50 mg tablet once a day for those starting antiretroviral therapy for the first time, or for those who have not used an integrase inhibitor in the past.

One 50 mg tablet twice a day for treatment-experienced individuals who have HIV that is resistant to other integrase inhibitors, and when taken with certain ARVs.

Pediatric Dose: For those who are starting antiretroviral therapy for the first time, or for those who have not used an integrase inhibitor in the past: one 50 mg tablet once a day for those who are at least 88 lbs (40 kg); one 10 mg tablet and one 25 mg tablet once a day for those who weigh 66 lbs (30 kg) to less than 80 lbs (40 kg).

Dosing Info: Take with or without food.


Side Effects

Common side effects include trouble sleeping, headache, tiredness.


Drug Interactions

For an overview of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Tivicay or may require dose adjustments, consult the Tivicay package insert.


Other Info

Before taking this medication, tell your doctor if you have kidney disease or liver disease (including hepatitis B). In addition, tell your doctor if you are pregnant or planning to become pregnant, if you are breast feeding, and all your medical conditions, including all prescription and over-the-counter medications and supplements you are taking.


For More Info: https://www.gsksource.com/gskprm/htdocs/documents/TIVICAY-PI-PIL.PDF

Co-Pay Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs

Patient Assistance Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs

Last Reviewed: August 7, 2020